December 11th 2024
Patients with ER-positive/HER2-negative metastatic breast cancer who received elacestrant experienced a significant reduction in disease progression or death compared with standard-of-care endocrine therapy.
October 24th 2024
Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.
Obesity May Fuel 40% Gap in Black, White Breast Cancer Mortality